Protein Conjugation As It Should Be:
Any Protein, Any Site, Any Cargo
Finally delivering on the promise of antibody-conjugates and protein therapeutics
BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy.
Having validated its precise and unrestricted conjugation capabilities through pharmaceutical co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™.
Bioconjugation is an effective tool used link multiple proteins or molecules together in order to synergistically enhance their therapeutic effect. In the past, the biotech industry has relied on suboptimal methods, resulting in a staggering number of failed therapeutics due to heterogeneity, lack of stability, or lack of precise control of the conjugation site, amongst other pitfalls.
BrickBio has solved these limitations
We Enable Safer, More Efficacious Therapeutics
BrickBio's precise conjugation technology and control over protein structure open a new world of engineering capabilities, resulting in best-in-class molecules
Proteins with enhanced half-lives, improved specificity, increased activity, mitigated drug-resistance, and overall improved therapeutic windows
Novel bispecific antibodies distinctly modified at two different sites, completely new avenues for therapeutic advances
Protein scaffolds with precise functional orientations, also referred to as Spatial Protein Assembly, resulting in therapeutics with unprecedented efficiency
Pipeline and pharma co-development efforts leverage our ADC platform as well as our Precise Protein-Origami™ pioneering efforts for novel therapeutics that will revolutionize the oncology and immunology treatment landscapes
BrickBio Advances the Conjugation Status Quo
Best-in class advancements of genetic code expansion from the Abhishek Chatterjee Lab and internal BrickBio R&D
Simple and rapid engineering of any protein to contain a bioconjugation handle at any site
Site-Select Panel driven by proprietary algorithm
BrickBio has the only solution spanning all aspects of conjugation
Precise, unrestricted and efficient site-control of conjugation
Arsenal of stable chemistries for conjugation with improved in vivo stability
Multiple compatible chemistries for precise combination
Highly efficient Mammalian (CHO) or bacterial expression
Optimal Therapeutics for Patients
BrickBio ADCs are 100x safer and more efficacious than industry ADCs
CEO, CO-FOUNDER,
TIGER GENE
VP, COMMERCIAL
DEVELOPMENT
SENIOR ADVISOR &
CHAIRMAN OF SAB
HEAD OF BUSINESS DEVELOPMENT
DIRECTOR, PROTEIN SCIENCES
DIRECTOR, CELL LINE DEVELOPMENT
At BrickBio, our highly collaborative team drives to make an impact in patient's lives through our revolutionary platform technologies. We're looking for determined leaders in biotech who are passionate, innovative, and want to set the bar high for the next generation of protein therapeutics.
12 Gill Street, Suite 4200
Woburn, MA, 01801, USA
For any general inquiries, please fill in the following contact form:
